Abstract. KRAS mutation status is being used as the sole biomarker to predict therapeutic efficacy of cetuximab in metastatic colorectal cancer (mCRC). A significant number of mCRC patients with KRAS wild-type (WT) tumors, however, do not benefit from cetuximab. We are also lacking efficacy predictors in head and neck squamous cell carcinomas with an intact KRAS signaling and in non-small cell lung cancer in which KRAS mutations do not predict cetuximab efficacy. We recently established pre-clinical models of EGFR gene-amplified KRAS WT A431 squamous carcinoma cells chronically adapted to grow in the presence of cetuximab. We employed the ingenuity pathway analysis software to functionally interpret data from Agilent's whole human genome arrays in the context of biological processes, networks, and pathways. Cetuximabinduced activation of the interferon (IFN)/STAT1 appeared to switch from 'growth inhibitory' in acutely-treated cells to 'prosurvival' in chronically-adapted cells. Cetuximab treatment appeared to negatively select initially dominant IFN-sensitive clones and promoted selection of IFN-and cetuximabrefractory tumor clones constitutively bearing an up-regulated IFN/STAT1 signaling. High-levels of mRNAs coding for the EGFR ligands amphiregulin (AREG), epiregulin (EREG), and neuregulin-1/heregulin (NRG1) predicted for acute cetuximab's functioning. Chronic cetuximab, however, appeared to negatively select initially dominant AREG/EREG/NRG1-positive clones to promote selection of cetuximab-refractory clones exhibiting a knocked-down neuregulin signaling. Our current evolutionary mapping of the transcriptomic changes that occur during cetuximab-induced chronic blockade of EGFR/KRAS WT signaling strongly suggests that mRNAs coding for IFN/ STAT1-and EGFR ligands-related genes can be evaluated as novel predictors of efficacy in KRAS WT squamous cancer patients being treated with cetuximab.
Introduction

'The presence of a wild-type KRAS does not predict response to cetuximab, but a mutant KRAS is associated with the high likelihood of nonresponse'
. This sentence is, at the present time, the sole Holy Grail for prediction of sensitive cetuximab response that clinicians can utilize before treating metastastic colorectal cancer (mCRC) with cetuximab-based regimens (2) . The presence of KRAS mutations has been consistently associated with a lack of response to cetuximab in a series of small observational studies [i.e., mCRC patients with KRAS mutations had significantly shorter time to tumor progression compared with KRAS wild-type (WT) mCRC patients whereas tumors not harboring KRAS mutations were more likely to decrease in size upon treatment]. Importantly, the association between KRAS status and outcome appears to be maintained across lines of treatment and in both monotherapy and combination settings (with the exception of first-line dual biological combination of Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux ® ) efficacy in KRAS wild-type squamous carcinomas: A pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models anti-VEGF and cetuximab) (3) . Retrospective analyses of larger randomized clinical trials have further cemented a pivotal role of KRAS mutations as predictors of lack of benefit with cetuximab treatment (4, 5) . In this scenario, KRAS gene mutation status as selection parameter poses a tremendous logistic challenge in the actual testing of tumors in mCRC because there is currently no US Food and Drug Administration-approved standardized KRAS mutation detection test (6) . Moreover, having an intact KRAS gene is necessary but not sufficient to derive benefit from cetuximab in EGFR-driven mCRC (6, 7) . With KRAS mutations accounting for approximately 30-40% patients who are not response to EGFR-targeted therapies including cetuximab and panitumumab, it is obvious that we need to develop novel treatment alternatives for mCRC patients bearing KRAS mutations. Given that a significant number of patients with KRAS WT do not benefit from cetuximab therapy (i.e., less than half of KRAS WT mCRC patients will benefit from cetuximab treatment) (8), we should consider further selection based not only on KRAS mutational status but also on additional potential predictors of benefit from cetuximab. Elucidating mechanisms by which mCRC exhibit de novo refractoriness (i.e., failure of cetuximab to elicit any detectable response to initial treatment) and acquired auto-resistance (i.e., progression of a mCRC that had previously responded to treatment, despite continued administration of cetuximab) may be critical to improving the successful clinical management of mCRC patients treated with cetuximab. We should therefore increase also our scrutiny for molecular mechanisms of resistance and predictive biomarkers in KRAS WT mCRC patients. In this regard, we are beginning to accumulate evidence that mRNA levels of the EGFR-ligands amphiregulin (AREG) and epiregulin (EREG) can be employed as potential predictors of response to cetuximab among KRAS WT mCRC patients. Using a pharmacogenomic approach in pre-treatment biopsies from metastatic sites, Khambata-Ford et al pioneeringly reported that high expression levels of AREG and EREG were highly predictive of clinical outcome from cetuximab monotherapy in mCRC (9) . In their hands, constitutive expression of AREG and EREG in EGFR-positive L2987 lung carcinoma cells was stimulated by EGF treatment and decreased upon exposure to cetuximab. Since cetuximab-induced inhibition of EGFRdependent L2987 cell growth was accompanied by coordinated down-regulation of AREG and EREG, the authors suggested that these EGFR ligands should be considered beacons of an activated EGFR pathway and perhaps a necessary positive feedback loop for cetuximab efficacy. From a clinical perspective, a significant correlation between expression of AREG and EREG and outcome of mCRC patients treated with cetuximab-based regimens has been confirmed in other studies (10, 11) . Further expanding the highly significant ability of AREG and EREG to predict response and survival benefit after treatment with cetuximab, Jacobs et al revealed that high levels of AREG and EREG mRNAs in the primary tumor positively associate with increased responsiveness to cetuximab (12) . When assessing the predictive effect of a) high versus low EREG among KRAS WT and b) high EREG/KRAS WT status ('combimarker') versus all other patients on overall survival and progression-free survival, Jonker et al recently reported that mCRC patients with both high EREG gene expression and KRAS WT status did benefit from significantly larger cetuximab treatment effects (13) .
In addition to high expression levels of AREG and EREG, mRNA expression levels of the MAPK phosphatases DUSP4 and DUSP6 have been also suggested as predictor candidates of outcome after cetuximab treatment in KRAS WT and mutant mCRC (14) . DUSPs are key regulators of the balance between MAP kinase pathway activation and inactivation and have previously been reported to be up-regulated in an adaptive response, thus creating a negative feedback loop following MAPK pathway activation (15, 16) . Indeed, DUSP4 and DUSP6 were originally identified as top resistance markers to cetuximab in unselected patients and the use of a four-gene expression model, including AREG, EREG and DUSP6 (as well as SLC26A3 -solute carrier family 26 member 3) has been shown to improve the identification of responders among pre-selected KRAS WT mCRC (9, 11) . Recently, Montagut et al have revealed that DUSP4 protein can be considered a promising negative marker of response to cetuximab-based treatment in mCRC with WT KRAS (17) . When they assessed DUSP4 expression by immunohistochemistry in a small series of mCRC patients, overexpression of DUSP4 protein significantly associated with lower response rates and shorter median time to progression among KRAS WT patients (17) .
The development of pre-clinical models exhibiting long-term adaptation to cetuximab can be highly desired to preliminary elucidate if changes in the expression status of EGFR ligands relate to the occurrence of cetuximab refractoriness. We recently envisioned that cetuximab-imposed chronic prevention of binding of the EGFR ligands to the EGFR receptor should provoke a long-term deactivation of the EGFR/RAS/MAPK signaling cascade that might generate cetuximab-adapted tumor cells bearing molecular features equivalent to those expected in the important sub-group of KRAS WT mCRC patients that do not benefit from cetuximab ab initio. We established pre-clinical models of EGFR-positive A431 vulvar squamous carcinoma cells chronically adapted to grow in the continuous presence of cetuximab. A431 epidermoid carcinoma cells were chosen based on three primary criteria: a) these EGFR-overexpressing cells are exquisitely sensitive to cetuximab; b) A431 cells has not either EGFR tyrosine kinase domain or KRAS mutations, and c) apoptotic cell death is usually weak or sometimes not observed after cetuximab treatment (i.e., cetuximab-induced EGFR down-regulation effectively abrogates mitogenic signals from autocrine or paracrine growth factors, thus resulting in arrest of cell cycle progression but nor active cell killing) (18) (19) (20) . In this scenario, we aimed to minimize the detection of gene expression changes related to general alterations in the apoptotic cell machinery among the transcriptional events induced by chronic cetuximab-induced EGFR inhibition. Our results confirm a crucial role for EGFR ligands in dictating the outcome in response to cetuximab treatment and reveal for the first time that tumor clones that constitutively exhibit high transcriptional levels of interferon (IFN)/STAT pathway expression, and are thus resistant to the cytotoxic effects of this pathway, are preferentially selected by chronic exposure to molecularly targeted agents such as cetuximab. We propose for the first time that loss of the main mechanism for EGFR activation (i.e., autocrine/paracrine loop by EGFR ligands) together with overexpression of the INF/STAT1 pathway may actively contribute to cetuximab refractoriness and cancer relapsing during cetuximab-based therapy.
Materials and methods
Materials.
RayBio™ Human Cytokine Array 3 (Cat no. AAH-CYT-3) was purchased from RayBiotech, Inc. (Norcross, GA, USA). Cetuximab (Erbitux ® ) was kindly provided by Hospital Universitari de Girona Dr Josep Trueta Pharmacy (Girona, Spain). Cetuximab was solubilized with 10 mmol/l NaCl of potassium phosphate buffer (PBS) pH 7.2 in bacteriostatic water for injection purposes (stock solution at 2 mg/ml), stored at 4˚C and used within 1 month.
Culture conditions. Parental A431 vulvar squamous carcinoma cells (originally obtained from the American Type Culture Collection, Manassas, VA, USA) were routinely grown in Dulbecco's modified Eagle's medium (DMEM, Gibco ® Cell Culture Systems, Invitrogen S.A., Barcelona, Spain) containing 10% heat-inactivated fetal bovine serum (FBS, Bio-Whittaker, Inc., Walkersville, MD, USA), 1% L-glutamine, 1% sodium pyruvate, 50 U/ml penicillin, and 50 µg/ml streptomycin. Cells were maintained at 37˚C in a humidified atmosphere of 95% air/5% CO 2 . Cells were screened periodically for Mycoplasma contamination.
Establishment of long-term (LT)-cetuximab adapted KRAS WT tumor cell populations.
Commencing with the IC 50 of cetuximab (~25 µg/ml) against A431 parental cells, the exposure dose of cetuximab was progressively increased 2-3 weeks until four dose doubling had been successfully achieved. Controlled parental cells were cultured strictly in parallel and exposed to the phosphate-buffered saline (PBS) vehicle. This approach resulted in the establishment of two LT-cetuximab adapted A431 POOLs that were then maintained in continuous culture with the maximal achieved dose of cetuximab. When challenged to cetuximab doses as high as 200 µg/ml, LT-cetuximab A431 POOL1/2 retained a >90% active metabolic status (as assessed by MTT-based cell viability assays) compared to cetuximab-naïve A431 parental cells (which decreased their ability to metabolize MTT by ~50% following treatment with 200 µg/ml cetuximab).
Agilent GeneChip analyses.
Total RNA isolated from A431, LT-cetuximab A431 POOL1, LT-cetuximab A431 POOL2 cells grown in the absence of cetuximab was isolated with TRIzol reagent (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's instructions. RNA quantity and quality were determined using the RNA 6000 Nano Assay kit on an Agilent 2100 BioAnalyzer (Agilent Technologies, Palo Alto, CA, USA), as recommended. Agilent human whole genome microarrays (G4112F), containing 45,220 probes, were then hybridized. Briefly, 500 ng of total RNA from each sample were amplified by Oligo-dT-T7 reverse transcription and labeled by in vitro transcription with T7 RNA polymerase in the presence of Cy5-CTP or Cy3-CTP using the Quick Amp Labeling Kit (Agilent) and purified using RNAeasy columns (Qiagen). After fragmentation, 825 ng of labeled cRNA from each of the two samples were co-hybridized in in situ hybridization buffer (Agilent) for 17 h at 65˚C and washed at room temperature (RT) 1 min in Gene Expression Wash Buffer 1 (Agilent) and 1 min at 37˚C in Gene Expression Wash Buffer 2 (Agilent).
Statistical analysis of microarray data. The images were generated on a confocal microarray scanner (G2565BA, Agilent) at 5 µm resolution and quantified using GenePix 6.0 (Molecular Dynamics). Spots with signal intensities twice above the local background, not saturated and not flagged by GenePix were considered reliable. Extracted intensities were background-corrected and the log2 ratios were normalized in an intensity-dependent fashion by the global LOWESS method (intra-chip normalization). Normalized log2 ratios were scaled between arrays to make all data comparable. Raw data were processed using MMARGE, a web implementation of LIMMA -a microarray analysis library developed within the Bioconductor project in the R statistical environment. To determine genes that were differentially-expressed, the multiclass SAM (significance analysis of microarrays) procedure was applied. Probes with q-value (FDR) below 5% and additionally a fold change exceeding 2.0 in absolute value were initially selected as the relevant ones. Microarray probes were collapsed to genes by taking the median log2 ratio of the respective probes per gene.
Ingenuity analysis. Gene networks were constructed using ingenuity pathway analysis (Ingenuity ® Systems, Redwood City, CA, USA). Data sets containing identifiers of genes with >2.0-fold up-and down-regulatory changes were uploaded into the application. These 'focus genes' were overlaid onto a global molecular network developed from information contained in the ingenuity pathway knowledge base. Networks of these 'focus genes' (nodes) are algorithmically generated based on the principle that highly connected gene networks are most biologically meaningful. All edges are supported by, at least, one reference from the literature stored in the ingenuity pathway knowledge base (the IPA interaction database is manually curated by scientists and updated quarterly). Briefly, the user-input or 'focus genes' gene list is compared to the 'global molecular network' (GMN) database consisting of thousands of genes and interactions. The focus genes are sorted based on highest to lowest connectivity within the GMN, and then networks of approximately 35 genes are grown starting with the most connected focus gene. IPA assigns a p-value for a network of size n and an input focus gene list of size f by calculating the probability of finding f or more focus genes in a randomly selected set of n genes from the GMN. The intensity of the node color indicates the degree of expression (green scale for downregulated nodes; red scale for up-regulated nodes). Nodes are displayed using various shapes each representing functional class of the gene product. The score indicates the likelihood of the genes in a network being found together because of random chance. Using a 99% confidence interval, scores of ≥3 are significant.
Conditioned medium.
To prepare conditioned medium, cells were plated in 100-mm tissue culture dishes and cultured in DMEM with 10% FBS until they reached 75-80% confluence. Cell cultures were then washed twice with serum-free DMEM, and incubated overnight in serum-free DMEM. Cells were finally cultured for 48 h in low-serum (0.1% v/v FBS) DMEM. The supernatants were collected, centrifuged at 1,000 x g, aliquoted, and stored at -80˚C until testing.
Cytokine antibody arrays. Assays for cytokine antibody arrays was carried out as per the manufacturer's instructions with minor modifications. Briefly, cytokine array membranes were blocked with 5% BSA/TBS (0.01 mol/l Tris-HCl pH 7.6/0.15 mol/l NaCl) for 1 h. Membranes were then incubated with about 2 ml of conditioned media prepared from different cell lines at 4˚C for overnight. After extensive washing with TBS/0.1% v/v Tween-20 (3 times, 5 min each), the membranes were incubated with a cocktail of biotin-labeled antibodies against different, individual cytokines. The membranes were washed and incubated with HRP-conjugated streptavidin (2.5 pg/ml) for 1 h at room temperature. Unbound HRP-streptavidin was washed out with TBS/0.1% v/v Tween-20 and TBS. The signals were finally detected by ECL system. Densitometric values of spots were quantified using Scion Imaging Software (Scion Corp., Frederick, MD, USA).
Results
First, we performed genome-wide analyses by comparing global transcriptomic profiles of cetuximab-naïve A431 parental cells and A431-derived cetuximab-adapted A431 POOLs. After RNA hybridization to Agilent 44K (double density) whole human genome oligo microarray (containing 45,220 features -probes -representing 41,000 unique human genes and transcripts), normalized and filtered data from cetuximab-responsive A431 parental cells and cetuximabunresponsive A431 POOLs were both analyzed simultaneously using the significance analysis of microarray (SAM) algorithm. We set the significance cut-off at a median false discovery rate (FDR) of <5.0%. Using a 2.0-fold change cut-off relative to the transcriptome of cetuximab-naïve A431 parental cells, and when identification of genes that showed significant expression changes was made only considering well-annotated transcripts (not partial cds for hypothetical proteins, hypothetical insert cDNA clones, etc.) and genes that could not be identified were rule out, the analysis software package ingenuity pathway analysis (IPA, Ingenuity System Inc., USA) identified 731 and 848 genes differentially-expressed in LT-cetuximab adapted A431 POOL1 and POOL2, respectively (Fig. 1) . We decided to investigate the overlap of 473 genes (43%) between the gene signatures obtained from both LT-cetuximab adapted A431 POOLs (1106 genes in all were differentially-expressed in both the cetuximab-adapted POOL1 and the cetuximab-adapted Figure 1 . Top: A schematic depicting the experimental approach designed to establish long-term (LT) cetuximab-adapted populations (pools) of KRAS WT tumor cell populations. LT-cetuximab adapted A431 POOLs may contain cells with various degrees of cetuximab resistance. Also, the POOLs developed during the study may harbour resistance acquired over time or may represent a selected subpopulation of cells with inherent resistance. Despite these drawbacks to our approach, POOLs also represent the alterations that are represented in the majority of heterogeneous tumor cell populations, whereas clones -another approach that would have been used to answer our research question -represent just one isolated alteration. Bottom: Ven diagram showing overlap in genes whose expression is significantly altered following acquisition of resistance to cetuximab-induced cell growth inhibition. To investigate how A431 cells adapted to grow in the continuous presence of cetuximab, we performed gene-expression profiling experiments. RNA was extracted from POOL1, POOL2 and parental A431 cells. The RNA was then hybridized to G4112F Agilent human whole genome microarray chips, and gene expression was analyzed as described in Materials and methods. Tables I and II summarize gene transcripts up-and down-regulated, respectively, in the overlapping 'cetuximab unresponsiveness-transcriptomic signature'. Second, the 'core analysis' function included in IPA software was employed to interpret the above data in the context of biological processes, networks, and pathways. Networks of up-and down-regulated functionally-related annotated genes were algorithmically generated by IPA based on their connectivity and assigned a score (i.e., a numerical value that takes into consideration both the number of focus genes in a network and the size of the network to approximate how relevant this network could be to the original list of focus genes). IPA analysis revealed 14 gene networks significantly up-regulated and 12 gene networks significantly down-regulated (scores of ≥3) within the 'cetuximab unresponsiveness-transcriptomic signature'. Table III summarizes the IPA-recognized gene networks with the ten highest scores of overexpressed (bold) and down-regulated (underlined) transcripts. Third, 'canonical pathways analysis' identified the pathways, from the IPA library of canonical pathways, which were most significant to the input data set. The significance of the association between the data set and the canonical pathway was determined based on two parameters: a) a p-value calculated using Fischer's exact test determining the probability that the association between the genes and the canonical pathway is due to chance alone, and b) a ratio of the number of genes from the data set that map to the pathway divided by the total number of genes that map to the canonical pathway. Table IV lists the top 5 canonical pathways that were up-and down-regulated within the 'cetuximab unresponsiveness-transcriptomic signature'. (Fig. 2a) , including genes coding for members of the tumor necrosis factor receptor superfamily (TNFRS9, TNFRS14, TNFRS21) that have crucial roles in both innate and adaptive immunity (21), several interferon (IFN)-related inflammatory markers such as genes encoding for members of the 2'-5'oligoAdenylate Synthetase family (OAS1, OAS2, OAS3) (22, 23) , and several keratins involved in epidermal cell differentiation/keratinization (KRT13, KRT14, KRT15, KRT19) (24) . This gene network was identified around the major pro-inflammatory cytokine tumor necrosis factor (TNF)-α; b) anti-microbial response, antigen presentation, cell-to-cell signaling and interaction (Fig. 2b) , including baculoviral IAP (inhibitor of apoptosis protein) repeat-containing 3 (BIRC3) (25) , a homologous of c-IAP2 (cellular inhibitor of apoptosis protein 2) that plays a critical role in resistance to toll-like receptor 3 (TLR3)-mediated apoptosis (26) (27) (28) as well as members of the TNF cytokine superfamily including TNF and lymphotoxins alpha and beta (LTA, LTB) (29) . This gene network was identified around TNF/LT-regulated anti-apoptotic members of the NF-κ family; c) cellular growth and proliferation, hepatic system development and function, liver proliferation (Fig. 2c) , a gene network that was identified around IFN-γ and included several IFN-induced transcripts (e.g., the IFI6/IFI27 anti-apoptotic genes and the member of the HERC family of ubiquitin ligases HERC6) (30) (31) (32) .
Pathway-based analysis of genome-wide transcriptomic data reveals that signaling cascades related to 'inflammatory responses' are the crucial gene network functions overactivated in cetuximab-unresponsive KRAS WT tumor cells.
When IPA was used to determine canonical pathway analysis enrichment categories 'interferon signaling' (33) (34) (35) (36) was the most statistically significant map modulated by the up-regulated genes within the 'cetuximab unresponsivenesstranscriptomic signature' (Fig. 3a) . Cetuximab-accommodated :4940), ORM2, PMEPA1, PRKCDBP, PRR7, RB1, TGFBI,  THBD, TOPBP1, TP53, ZBTB11   5 ADSSL1, ANKH, ARAP3, BCHE, beta-estradiol, CA2, CAPRIN2, CDK18,  26  16  Dermatological  CLDN4, CSTA, FLOT1, GARS, GSTT1, HIST2H2BE, HOXA10, KRT7,  diseases and  KRT83, KRT86, KRT81 (includes EG:3887), MAOA, MFNG, MIR26B conditions, genetic (includes EG:407017), MSGN1, PDZK1IP1, phosphatidylinositol-3,4,5-disorder, drug triphosphate, progesterone, SLC27A2, SMPDL3A, TACSTD2, TFCP2L1, metabolism TRH, TSPAN5, WFDC2, WISP2, YWHAZ Gelatinase, GPR68, HCFC1R1, HMGCS2, KRT14, MMP9, NR3C1,  skeletal and muscular  PCSK6, Pdgf, PDGFA, POSTN, SLC29A1, SORBS3, TEAD4, TFEB,  system development and  THBD, TNFSF14, TPP1, VAV3, WASF3, WT1  function, tissue development   10 ACP5, CFDP1, COL6A1, DUSP4, Ecm, FCAR, GBP2, GPT2, GYLTL1B, 21  14  Cell death, gene expression,  HADH, HMGN5, HOXA2, IDI1, IL5, KCNG1, LIMK2, MIR124-1  cellular development  (includes EG:406907), NEUROG3, NOMO1, OAF, PORCN, PRDX4,  PRPS1, PYCR1, SLC5A5, SMAD3, SMURF2, SNAI2, TGFB1, TMED1,  TPSAB1, TWIST2, WISP1, WNT4, WNT5B The composite score of the networks represents the negative log of the p-value for the likelihood that network molecules would be found together by chance. A higher score indicates greater statistical significance that molecules depicted in the network are interconnected. cell populations appear to up-regulate members of the interferon signaling-input layer [i.e., the interferon gamma receptor (IFNGR1, ↑2.31-fold)], of the interferon signal-processing layer [i.e., the transcription factor signal transducer and activator of transcription 1 (STAT1, ↑2.1-fold)], which binds to the cyto plasmic portion of ligand-activated IFN-γ receptor and is phosphorylated by JAKS to cause STAT1/STAT1 and/or STAT1/STAT2 dimerization, nuclear translocation and binding of STAT1 to its cognate promoter DNA, the gamma interferonactivated site (GAS), and of the interferon signaling-output layer [i.e., STAT1-dependent transcription of the interferoninducible genes IFIT1 (↑2.26-fold), IFITM1 (↑2.48-fold), IRF9 (↑4.1-fold), MX-1 (↑6.69-fold), MX-2 (↑6.44-fold), OAS1 (↑2.89-fold), OAS2 (↑2.81-fold), and OAS3 (↑2.27-fold), which are markers of enhanced interferon bioactivity].
Pathway-based analysis of genome-wide transcriptomic data reveals that 'retinoic acid' and 'neuregulin' signaling cascades are the crucial gene network functions down-regulated in cetuximab-unresponsive KRAS WT tumor cells. Fig. 2 (bottom panels) illustrates graphically the 3 top gene network functions significantly down-regulated within the 'cetuximab unresponsiveness-transcriptomic signature'. Top functions of up-regulated gene networks were related to: a) lipid metabolism, molecular transport, small molecule biochemistry (Fig. 2a') , including genes implicated in fatty acid synthesis, uptake, transported and metabolism such as stearoyl-coenzyme A (SCD) (37), apolipoprotein C1 (APOC1) (38) and fatty acid binding protein-6 (FABP6) (39) as well as genes coding for isoforms of the platelet-derived growth factors (PDGFA, PDGFB) and the guanosine nucleotide exchange factors (GEFs) Vav and Vav2, two members of the Vav family of proto-oncogenes that couple activation of multiple cell surface receptors (EGFR, PDGFR) to actin cytoskeletal rearrangements and transcriptional alterations during chemotactic-cell migration responses (40) (41) (42) . This gene network, which also included the regulator of PDGF-induced activation of ERK (MAPK) DUSP6 (also called MKP3) (43) , was identified around PDGFBB and NF-κB complex. b) Gene expression, cellular development, connective tissue development and function (Fig. 2b') , including the cell cycle regulators CDKN2A (also called MTS-1 or p16) and TP63 (44, 45) as well as the angiogenic/metastatic factors hypoxia-inducible factor 1 alpha (HIF1A) and vascular endothelial growth factor (VEGF) (46, 47) . This gene network, which included also EMT-related genes such as SNAI2 (often called SLUG) -a pivotal transcription factor that initiate EMT transitions throughout development and in cancer metastasis (48) , and prostate transmembrane protein, androgen induced 1 (PMEPA1), a TGFβ-induced marker of terminal colonocyte differentiation whose expression is maintained in primary and metastatic colon cancer (49) , was identified around p38 MAPK. c) Cancer, lymphoid tissue structure and development, organismal development (Fig. 2c') , including genes closely related to cell adhesion/migration and angiogenesis such as VEGFA, members of the integrin family (ITGA5) (50) , and the B1 and B2 members of the Ephrin receptor family (EFBN1, EFBN2) (51, 52) . This gene network was identified around the gene coding for the cetuximab target itself (i.e., EGFR). When IPA was used to determine canonical pathway analysis enrichment categories 'FXR/RXR activation' and 'neuregulin signaling' (Fig. 3a) were the most statistically significant maps modulated by the up-regulated genes within the 'cetuximab unresponsiveness-transcriptomic signature'. Cetuximab-accommodated cell populations appear to speci- (Table IV) .
fically down-regulate several members of the neuregulin signaling-input layer (53) (54) (55) 
Discussion
Early clinical studies demonstrated that immunohistochemistry-based assays measuring expression of the cetuximab target EGFR does not serve as a robust predictor for response (i.e., CRC patients can exhibit major objective response to cetuximab despite the absence of measurable EGFR) (56) . In the same regard, no mutations in EGFR gene have been identified to date that are reliably predictive for response to cetuximab-based EGFR therapies (57) . Although KRAS and BRAF mutations in primary CRC are predictive of nonresponse to cetuximab in patients with mCRC, an intuitive mechanism of primary resistance to cetuximab may relate to the presence of KRAS or BRAF mutations only in metastases. However, several recent studies have concluded that acquisition by metastases of a KRAS or a BRAF mutation that was not originally present in the primary tumor is a rare event that occurs solely in up to 5% of cases of mCRC (58) (59) (60) . These studies have confirmed that a high concordance between the mutation status of KRAS and BRAF occurs in primary CRC and in corresponding metastases, therefore suggesting that other molecular mechanisms should exist that modulate intrinsic (primary) and/or acquired (secondary) resistance to cetuximab. De Reyniès et al, when testing the performance of the top genes of the cetuximab response signature for their ability to separate KRAS WT from mutant tumors, obtained clusters of samples highly associated to mutation in KRAS and in the serine-threonine kinase BRAF -the principal effector of KRAS (61) . Given that BRAF WT is required also for response to cetuximab and could be used to select mCRC patients who are eligible for treatment (62) , KRAS mutation signatures in mCRC significantly overlaps with the cetuximab response signature. In this study, the expression signature of the response to cetuximab monotherapy was obtained in a disease control population significantly enriched for KRAS WT patients relative to the nonresponder population. Therefore, it is reasonable to argue that we should expect a significant overlapping between set of genes that are associated with disease control after cetuximab treatment and sets of genes that are differentially-expressed as a function of KRAS mutational status (61) . Indeed, there is a significantly higher expression of the mRNAs of DUSP4 and DUSP6 in KRAS mutant compared to WT mCRC treated with cetuximab and high DUSP4 expressing WT KRAS tumors may have undetected KRAS or BRAF mutations (14) . Further supporting this notion of an inherent overlap between KRAS mutation and cetuximab response signatures, the EGFR ligands EREG, HB-EGF (heparin-binding EGF-like growth factor) and BTC (betacellulin) as well as the MAPK phosphatases DUSP4 and DUSP6, have been all found to be co-up-regulated among the multiple genes induced by several activating KRAS mutations (including those in the KRAS hotspots codons 12 and 13 and a novel ones outwith hotspot codons) in NIH-3T3 fibroblasts (63) .
Because molecular mechanisms other than activating KRAS mutations should modulate the occurrence of either weaker or stronger responses to cetuximab in tumors with an intact regulation of RAS signaling, we here envisioned that KRAS WT tumor cell-line models chronically exposed to cetuximab can be interrogated to obtain novel exploratory biomarkers for cetuximab efficacy. By tracking the evolution of transcriptomic changes during cetuximab-induced chronic prevention of EGFR activation and long-term deactivation of EGFR/RAS/MAPK pathway as determined by pathway-based functional analysis of whole human-genome microarray data, we confirmed that cetuximab is significantly more effective at inhibiting the growth of EGFRpositive KRAS WT tumor cells overproducing the EGFR ligands (e.g., AREG, EREG) compared with those producing low amounts of EGFR ligands. Yonesaka et al pioneeringly focused on ligand-mediated activation of EGFR and identified autocrine production of AREG as an important biomarker associated with growth inhibition by cetuximab in non-small cell lung cancer (NSCLC) cell lines and patients (64) . In their hands, cell lines overproducing AREG were significantly more likely to be growth inhibited by cetuximab than those that produced minimal or no AREG. Our current study shows that expression of AREG and EREG as assessed by microarray analyses may be an appropriate biomarker for identifying patients who will benefit from treated with cetuximab. Indeed, it is reasonable to suggest that, in terms of EGFR ligands and neuregulin signaling, the most significant distinction between primary and secondary refractoriness to cetuximab appears to be just the timing of detection. AREG and EREG mRNAs have been considered beacons of an activated EGFR pathway as part of a necessary positive feedback loop for cetuximab efficacy. Thus, EGFR ligands such as AREG stimulate the growth of cetuximab-sensitive cells whereas inhibition of the EGFR ligand expression alone (either by a neutralizing antibody, or by siRNA) is sufficient to inhibit cell growth (64) . Given that acute treatment with cetuximab rapidly down-regulates the mRNA expression levels of AREG and EPI in cetuximab-naïve tumor cells including A431 parental cells (9; data not shown), it is reasonable to suggest that the occurrence of AREG/EREG-mediated autocrine activation of EGFR is sufficient and necessary to allow functioning of cetuximab in EGFR-positive KRAS WT tumor cells. We can hypothesize that chronic exposure to cetuximab negatively select initially dominant (cetuximab-sensitive) AREG/EREG-positive clones and promote selection of (cetuximab-refractory) tumor clones constitutively bearing a down-regulated neuregulin signaling cascade (Fig. 4) . The ability of accurately establish an 'AREG/ EREG mRNA threshold' that clinically predicts functioning of cetuximab may indirectly inform about the intra-tumor clonal heterogeneity of AREG/EREG mRNA status during tumor progression and treatment. This strategy may help select KRAS WT mCRC patients before initiation of cetuximab-based treatments to avoid the rapid selection of existing cetuximabresistant AREG/EREG-negative clones.
Given that IFN/STAT1 signaling has traditionally been connected with pro-apoptotic tumor-suppressor functions (30, 31, (33) (34) (35) (36) 65) , an adaptive scenario analogous to that described above for the down-regulated AREG/EREG mRNA expression status may account for the counterintuitive up-regulation of the IFN/STAT1 signaling in KRAS WT tumor cell populations chronically adapted to grow in the presence of cetuximab. Emerging data begin to reveal that, in certain cellular contexts, the IFN/STAT1 pathway may mediate tumor cell growth, meta- static potential and resistance to certain therapies. Khodarev et al pioneeringly revealed that a radioresistant tumor that was selected against fractionated ionizing radiation from a radiosensitive parental tumor (and resistant to IFN-mediated cytotoxicity) constitutively overexpressed the IFN/STAT1 pathway (66, 67) . Recent studies have confirmed that constitutive induction of the STAT1 signaling positively associates with protection of tumor cells from genotoxic stress following treatment with fludarabine (68), doxorubicin (69), cisplatin (70) , and the combination of ionizing radiation with doxorubicin (71). Our current findings confirm and expand further the notion that IFN/STAT1 pathway overexpression not only relates to resistance to cytotoxic therapy including radiation and chemotherapy but also to molecularly targeted treatments such as the anti-EGFR monoclonal antibody cetuximab. Khodarev et al have recently demonstrated that tumor clones that constitutively overexpress the IFN/STAT1 pathway appear to be positively selected by tumor microenvironment due to a resistance to STAT1-dependent cytotoxicity and demonstrate increased metastatic ability combined with increased resistance to IFN and genotoxic stress relative to parental, low-expressors of the IFN/STAT1 signaling pathway (72) . In our hands, acute treatment of A431 parental cells with high-dose cetuximab (i.e., 100 µg/ml) was found to notably up-regulate gene expression for the IFN/JAK/STAT1 pathway as part of the transcriptomic signature associated with cetuximab-induced cell growth inhibition (data not shown). Upon chronic exposure to cetuximab, therefore, activation of the IFN/STAT1 pathway appears to paradoxically switch from 'growth inhibitory' to 'pro-survival' in response to cetuximab-induced cell injuries. This molecular switch can be explained when considering the pre-existence of clones inherently resistant to the cytotoxic effectors of the IFN/ STAT1 signaling pathway that overexpress STAT1-regulated genes with pro-survival functions [e.g., IFITM1 (73)] and they are intrinsically resistant to a wide variety of tumoricidal insults including blockade of EGFR-driven tumor growth promoting signaling. We can hypothesize that chronic exposure to cetuximab negatively select initially dominant IFN-sensitive clones and promotes selection of IFN-refractory tumor clones constitutively bearing an up-regulated IFN/STAT1 signaling cascade (Fig. 4) .
KRAS mutation status is being used as a biomarker to predict cetuximab therapeutic efficiency but it is not sensitive enough to determine the absolute indication of cetuximab in mCRC with an intact KRAS signaling pathway. The expression (or lack thereof) of other biomarkers should, therefore, actively regulate weaker or stronger responses to cetuximab. Because molecular mechanisms other than activating KRAS mutations should modulate intrinsic (de novo) and secondary (acquired) resistance to cetuximab in tumors with an intact regulation of RAS signaling, pre-clinical development and characterization of cultured cetuximab-resistant KRAS WT tumor cells might elucidate molecular features equivalent to those expected in the important sub-group of KRAS WT mCRC patients that do not benefit from cetuximab. In this regard, an ever-growing body of research with cultured cancer cells has substantially enhanced our current understanding of the molecular mechanisms implicated in resistance to the anti-EGFR antibody cetuximab including (reviewed in ref. 74): a) overexpression of the EGFR ligand transforming growth factor-α (TGF-α) (75); b) overexpression/overactivation of the cetuximab target (EGFR; HER1) itself and of other HER family members (HER2, HER3) (76, 77) ; c) dysregulation of EGFR internalization or degradation upon alteration of EGFR ubiquitination (76-78); d) subcellular distribution of EGFR and/or altered EGFR trafficking (79, 80) ; enhanced expression of VEFG/VEGFR (81) (82) (83) ; and occurrence of epithelial-to-mesenchymal transition (EMT) (84) . Obviously, this evolving list that has been generated using pre-clinical models may provide new candidate molecules capable to predict resistance to cetuximab, but all of them lack a definitive validation as clinically useful predictive biomarkers. Our current findings on neuregulin and IFN/STAT1 signaling are also hypothesis-generating and need to be further validated in prospective clinical studies and furthermore in paired primary and metastatic tumor specimens from cancer patients that have not been treated with cetuximab to determine the prognostic and/or predictive nature of these exploratory biomarkers. It should be noted, however, that unlike EGFR mutations, which are almost uniformly restricted to NSCLC (85) and KRAS mutations, which are informative of cetuximab inefficacy solely in mCRC (86, 87) , the expression status of mRNAs coding for EGFR ligands (e.g., AREG and EREG) and INF-related genes may be appropriate biomarkers for identifying patients who will benefit from treated with cetuximab in cancers other than CRC [e.g., for locally/regionally advanced head and neck squamous cell carcinoma (HNSCC) in combination with radiotherapy and as monotherapy for recurrent/metastatic HNSCC after failing platinum-based chemotherapy] in which this EGFR-targeted antibody is widely in clinical use (88) (89) (90) .
In conclusion, the feasibility of monitoring the expression status of neuregulin and INF/STAT1 signaling pathways by performing serial fine-needle aspirations and/or core biopsies to provide enough material for mRNA-based profiling studies might be explored in future studies as it may confirm AREG, EREG and/or IFN/STAT1-regulated genes as important predictors of response during and after cetuximab treatment in patients bearing KRAS WT tumors. Provided that cancer cells are shed into the circulation proportional to their clonal frequency, quantitative real-time RT-PCR analyses of AREG, EREG and/or IFN/ STAT1 mRNA markers originating from circulating tumor cells (CTC) during cetuximab therapy may provide direct evidence of positive or negative clonal selection (91) (92) (93) (94) , thus allowing early modification or adjustment of the therapeutic strategy before clinical progression to cetuximab will occur. Alternatively, the identification of soluble factors specifically secreted upon activation of pathway signatures using ELISAs or microarrays may predict the efficacy of cetuximab. For instance, activation of the IFN/STAT1 pathway leads to the induction of multiple prosurvival cytokines and radioresistance of STAT1-overexpressing tumor cells has been associated with increased production and secretion of interleukin-6 (IL6) and interleukin-8 (IL8) (73) , two genes which expression can be controlled through direct interaction of STAT1 with IL6 and IL8 gene promoters (95, 96) . Experiments in our laboratory using human cytokine antibody arrays to determine the profile of cytokines in conditioned media (97) from cetuximab-naïve A431 parental cells and from LT-cetuximab adapted A431 POOL1 and POOL2 confirmed that IFN/STAT1-overexpressing cetuximab-refractory cells likewise secrete significantly higher amounts of IL6 and IL8 as well as of IL10, GROα and MCP-1 (Fig. 5) . These findings suggest that circulating levels of IL6 and/or IL8 might represent unexpected novel biomarkers for monitoring tumor responses to cetuximab-based therapies. Obviously, our current identification of functional gene expression signatures as surrogate markers for understanding the efficacy of cetuximab at the molecular level should be integrated with parallel whole-transcriptomic analyses of clinical trial tissues to validate the robustness of these signatures to improve the identification of cetuximab responders and to predict therapeutic outcome of KRAS WT squamous carcinoma patients being treated with cetuximabcontaining regimens (98, 99) .
